$GRAL

Partridge Andrew John sold $91K of GRAL

Partridge Andrew John (Chief Growth Officer) sold 1,491 shares of GRAIL, Inc. (GRAL) at $61.08 on 2026-06-04.

Original reporting
SEC EDGAR · Partridge Andrew John
Published Jun 6, 2026, 12:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 6, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GRAL
Neutral
medium confidence
Mentioned
$GRAL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRALNeutralLow
01

Why it matters

This adds a new datapoint on insider behavior but does not introduce new operational or financial information about GRAIL.

02

Market read

Traders may briefly reassess sentiment around GRAL due to insider selling, but the filing alone is unlikely to change valuation materially.

03

What to watch

The article doesn’t state whether other insiders bought/sold, whether there were concurrent grants, or the broader insider trading pattern; one sale is not a trend.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 5; sale occurred June 4.

Background

The article is an SEC Form 4 insider transaction disclosure for GRAIL, Inc. (GRAL).

Company-level read

Ticker impact

$GRALNeutralMedium confidence
Context

GRAIL insider Chief Growth Officer Partridge sold 1,491 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

The filing provides a single sale datapoint without new company fundamentals (no guidance, trial, or deal). The absence of a 10b5-1 plan can increase interpretive noise, but the dollar amount (~$91k) is typically not material versus market cap.

Market effects

Minimal—this is company-specific insider activity with no stated sector-wide change.

None indicated.

None indicated.

Counterpoint

The sale may reflect diversification, liquidity needs, or tax planning rather than a bearish view, especially since insider transactions are often routine.

Key entities

  • GRAIL, Inc.

    Public company whose insider transaction was reported on SEC Form 4.

  • Andrew John Partridge

    Chief Growth Officer who sold 1,491 shares on June 4 (reported via Form 4).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GRALHighAI 8/10

Why GRAIL (GRAL) Is Up 8.1% And What's Next After Galleri FDA Backing

GRAIL (GRAL) shares rose 8.1% after an FDA advisory panel backed its Galleri blood test, citing strong clinical data. The test showed 99.64% specificity and 60.3% positive predictive value in detecting early-stage cancers. The company projects $348.4M revenue and $60.1M earnings by 2029, but analysts warn of reimbursement risks and high cash burn.

$GRALHighAI 8/10

Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

Grail's (GRAL) stock rose after an FDA advisory committee voted favorably on its Galleri test. The test, already available, needs insurer coverage for growth. FDA approval, likely following the vote, could prompt insurer evaluation. Insurers will assess cost-effectiveness and clinical utility. Grail's data shows Galleri's potential in detecting 12 deadly cancers.

$IOVAMedAI 8/10

Biotech Stocks At 52-Week Highs - IOVA +31%, XERS, GRAL, ABCL, SGHT

Several biotech stocks hit 52-week highs on September 29, 2026. Iovance (IOVA) rose 31% to $11.17, raising its revenue guidance to $410M-$420M. Xeris (XERS) reached $11.33, with updates on its XP-8121 program. AbCellera (ABCL) peaked at $14.82, with positive Phase 2 results for ABCL635. Grail (GRAL) hit $140.88 after FDA panel support for its Galieri test. Sight Sciences (SGHT) climbed to $9.71, reporting $23M in Q2 revenue, up 20% YoY.